Table 1. Clinico-pathological parameters from 107 prostatic adenocarcinoma patients.
|
PTEN
|
|||||
|---|---|---|---|---|---|
| Clinico-pathological parameters | Number of cases | Not deleted | Hemizygous | Homozygous | |
| Age median (min–max) | 61.9 years (48–69) | ||||
| Preoperative PSA (ng ml−1)a | P=0.556 | ||||
| 0.9–4.0 | 7 (6.7%) | 3 (42.9%) | 4 (57.1%) | 0 (0%) | |
| 4.1–10.0 | 55 (52.3%) | 32 (58.2%) | 22 (40%) | 1 (1.8%) | |
| 10.1–20.0 | 28 (26.7%) | 19 (67.8%) | 8 (28.6%) | 1 (3.6%) | |
| 20.1–84.0 | 15 (14.3%) | 6 (40%) | 8 (53.3%) | 1 (6.7%) | |
| Median tumour volume (%)a | P=0.158 | ||||
| 0–10.0 | 32 (34%) | 19 (59.4)% | 13 (40.6%) | 0 (0%) | |
| 10.1–20.0 | 19 (20.2%) | 12 (63.2%) | 7 (36.8%) | 0 (0%) | |
| 20.1–85.0 | 43 (45.8%) | 21 (48.9%) | 17 (39.5%) | 5 (11.6%) | |
| Gleason score | P=0.142 | ||||
| Gleason 4–6 | 61 (57%) | 39 (63.9%) | 20 (32.8%) | 2 (3.3%) | |
| Gleason 7 | 33 (30.8%) | 16 (48.48%) | 16 (48.48%) | 1 (3.03%) | |
| Gleason 8–9 | 13 (12.2%) | 5 (38.46%) | 6 (46.15%) | 2 (15.38%) | |
| Pathologic stage | P=0.569 | ||||
| pT2a | 6 (5.6%) | 1 (16.7%) | 5 (83.3%) | 0 (0%) | |
| pT2b | 49 (45.8%) | 30 (61.2%) | 16 (32.7%) | 3 (6.1%) | |
| pT3a | 32 (29.9%) | 18 (56.2%) | 13 (40.6%) | 1 (3.1%) | |
| pT3b | 13 (12.2%) | 4 (57.1%) | 3 (42.9%) | 0 (0%) | |
| pT4 | 7 (6.5%) | 4 (57.1%) | 3 (42.9%) | 0 (0%) | |
| Seminal vesicle invasion | P=0.859 | ||||
| Negative | 94 (87.9%) | 53 (56.4%) | 37 (39.4%) | 4 (4.2%) | |
| Positive | 13 (12.1%) | 7 (53.8%) | 5 (38.5%) | 1 (7.7%) | |
| Perineural infiltration | P=0.517 | ||||
| Negative | 15 (14.0%) | 10 (66.7%) | 5 (33.3%) | 0 (0%) | |
| Positive | 92 (86%) | 50 (54.4%) | 37 (40.2%) | 5 (4.4%) | |
| Angiolymphatic invasiona | P=0.346 | ||||
| Negative | 78 (77.2%) | 46 (59%) | 29 (37.2%) | 3 (3.8%) | |
| Positive | 23 (22.8%) | 10 (43.5%) | 11 (47.8%) | 2 (8.7%) | |
| Capsular invasion | P=0.729 | ||||
| Negative | 46 (43%) | 25 (54.4%) | 18 (39.1%) | 3 (6.5%) | |
| Positive | 61 (57%) | 35 (57.4%) | 24 (39.3%) | 2 (3.3%) | |
| Extraprostatic extensiona | P=0.713 | ||||
| Negative | 83 (81.4%) | 50 (60.2%) | 30 (36.2%) | 3 (3.6%) | |
| Positive | 19 (18.6%) | 9 (47.4%) | 8 (42.1%) | 2 (10.5%) | |
| Lymphonodal invasiona | P=0.812 | ||||
| Negative | 94 (95.9%) | 54 (57.4%) | 35 (37.2%) | 5 (5.3%) | |
| Positive | 4 (4.1%) | 2 (50%) | 2 (50%) | 0 (0%) | |
| Biochemical recurrence | P=0.005 | ||||
| Negative | 49 (46%) | 35 (71.4%) | 14 (28.6%) | 0 (0%) | |
| Positive | 58 (54%) | 25 (43.1%) | 28 (48.3%) | 5 (8.6%) | |
a
Values not available for all 107 cases.
Abbreviation: PSA, prostate-specific antigen.
Median overall survival was 80.65 months.
P-value=χ2 analysis.